BMO Capital Cuts Price Target as Tokai Pharma (TKAI) Stops ARMOR2 Trial Enrollment

August 23, 2016 7:40 AM

BMO Capital maintained a Market Perform rating on Tokai Pharmaceuticals (NASDAQ: TKAI), and cut the price target to $1.15 (from ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found